乙型肝炎肝硬化和肝癌患者肝组织HBV复制状态分析*

doi:10.3969/j.issn.1672-5069.2012.01.007

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (1): 21-22.doi: 10.3969/j.issn.1672-5069.2012.01.007

乙型肝炎肝硬化和肝癌患者肝组织HBV复制状态分析*

宋闽宁, 黄文琪, 闵峰, 洪美珠, 范荣华, 吴卫兵, 张丽, 李伟杰

361003 福建省厦门市厦门大学附属成功医院/解放军第174医院感染病科（宋闽宁,黄文琪,闵峰,洪美珠,范荣华,吴卫兵,张丽）; 北京解放军第302医院病毒性肝炎研究室（李伟杰）

收稿日期:2011-09-20 出版日期:2012-02-10 发布日期:2016-05-11
作者简介:宋闽宁女，57岁,主任医师。E-mail：luodqluojzsongmn2004@126.com
基金资助:
军区医学科技创新课题（编号：09MA061）

Hepatic hepatitis B virus replication status in patients with cirrhosis and primary liver cancer

Song Minning, Huang Wingqi, Min Feng, et al

Department of Infectious Diseases,the Affiliated Success/174th Hospital,Xiamen University,Xiamen 361003,Fujian Province,China

Received:2011-09-20 Online:2012-02-10 Published:2016-05-11

摘要/Abstract

摘要： 目的了解肝硬化和肝癌患者HBV的复制状态。方法在1982例肝癌和1995例乙型肝炎肝硬化患者,常规检测HBV标记物,并在其中12例患者取得肝组织进行HBVcccDNA检测。结果肝硬化和肝癌患者抗HBe阳性所占比例分别为61.7%和74%（P<0.01）;将肝硬化和肝癌患者合并后,血清抗HBe阳性者血清HBV DNA≤103拷贝/毫升者占69.1%,高于HBeAg阳性者的21.6%（P<0.01）;抗HBe阳性患者HBV DNA≥107拷贝/毫升者占6.4%,低于 HBeAg阳性者的42.0%（P<0.01）;HBeAg阳性和抗HBe阳性患者HBV DNA载量分别为6.1 lg拷贝/毫升和3.8lg拷贝/毫升（P<0.01）;在送检的12例肝组织,HBV DNA均阳性,HBVcccDNA阳性8例。结论肝硬化和肝癌患者抗-HBe阳性比例较高,肝组织HBVcccDNA仍可被检出。

关键词: 肝硬化, 肝癌, HBV标志物, HBVccc DNA

Abstract: Objective To investigate the hepatitis B virus replication status in patients with liver cirrhosis and primary liver cancer.Methods In 1982 patients with liver cancer and in 1995 with liver cirrhosis,serum HBV DNA and HBVcccDNA in liver tissues were detected.Results The serum anti-HBe positive rates in patients with liver cirrhosis and liver cancer were 61.7% and 74%,respectively（P<0.01）;in patients with serum anti-Hbe positive no matter with cirrhosis or cancer,the serum HBV DNA≤103copies/ml was 69.1%,much higher than 21.6% in patients with serum HbeAg positive（P<0.01）;in patients with anti-Hbe positive,serum HBV DNA≥107copies /ml was 6.4%,much lower than 42.0% in HbeAg positive（P<0.01）;in anti-HBe positive patients,serum HBV DNA levels was 3.8 lg copies/ml,much lower than in in HbeAg positive（6.1lgcopies/ml）;in 12 patients,all were hepatic HBV DNA positive,and 8 were hepatic HBV cccDNA positive.Conclution Patients with liver cirrhosis and liver cancer have a high percentage of serum anti-HBe positive,and HBV DNA or HBVcccDNA can be detected in liver tissues.

Key words: Cirrhosis, Hepatoma, HBV DNA, HBVccc DNA

宋闽宁, 黄文琪, 闵峰, 洪美珠, 范荣华, 吴卫兵, 张丽, 李伟杰. 乙型肝炎肝硬化和肝癌患者肝组织HBV复制状态分析*[J]. 实用肝脏病杂志, 2012, 15(1): 21-22.

Song Minning, Huang Wingqi, Min Feng, et al. Hepatic hepatitis B virus replication status in patients with cirrhosis and primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(1): 21-22.

参考文献

[1] 中华医学会肝病学分会和感染病学会.慢性乙型肝炎防治指南（2010年版）.实用肝脏病杂志,2011,14（2）：81-90.
[2] 中国抗癌协会肝癌专业委员会、中国抗癌协会临床肿瘤学协作专业委员会和中华医学会肝病学分会.原发性肝癌规范化诊治的专家共识.实用肝脏病杂志,2009,12（5）：321-328.
[3] 陈建国,陆建华,朱源荣,等.乙型肝炎病毒感染与肝癌发生的31年随访研究.中华流行病学杂志,2010,31（7）：721-726.
[4] Wu CF,Yu MW,Lin CL,et al. Long-time tracking of hepatitis B viral load and the rerationship with risk for hepatocellular carcinoma in men.Carcinogenesis,2008,29（1）:106-112.
[5] Thompson AJ,Nguyen T,Iser D,et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers:disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology,2010,51,（51）:1933-1944 .
[6] Gigi E,Lalla T,Orphanou E,et al.Long term follow-up of a large cohort of inactive HBsAg（+）/ HBeAg （-）/ anti-HBe（+） carriers in Greece. J Gastrointestin Liver Dis,2007,16（1）:19-22. [7] Nuguyen T,Alexander JV,Bowden BET,et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B:A perspective on Asia. J Hepatol,2010,52（4）:508-513.
[8] Chen CJ,Yang HI.Natural history of chronic hepatitis B revealed. J Gastroenterol Hepatol,2011,26（4）:628-638.
[9] Raza SA,Clifford GM,Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma:a systematic review.Br J Cancer,2007,96（7）:1127-1134.
[10] Wong DKH,Yuen MF,Poon RTP,et al. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma .Hepatology,2006,45 （4）:553-559.
[11] Levrero M,Pollicino T,Petersen J,et al.Control of cccDNA function in hepatitis B virus infection. J Hepatol,2009,51（3）:581-592.
[12] Gao YT,Han T,Li Y,et al. Enhanced specificity of real-time PCR for measurement of hepatitis B virus cccDNA using restriction endonuclease and plasmid-safe ATP-dependent DNase andselective primers. J Virol Methods,2010,169 （1）:181-187.

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[3]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[4]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[5]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[6]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[7]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[8]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[9]	王月圆, 王燕, 张丹丹. 奥曲肽辅助特利加压素治疗失代偿期肝硬化并发肝肾综合征患者疗效分析*[J]. 实用肝脏病杂志, 2019, 22(5): 684-687.
[10]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[11]	丹珠永吉, 刘芝兰, 禄艳艳, 蒋汉梅. 内镜下序贯套扎和硬化剂治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效及对血流动力学的影响对比研究*[J]. 实用肝脏病杂志, 2019, 22(5): 692-695.
[12]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[13]	赵芳芳, 翟永贞, 冯国和. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(5): 700-703.
[14]	陈山, 庄华帅, 邢诒喜, 吴直佳. 美罗培南治疗肝硬化并发上消化道出血患者对感染预防和再出血的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 704-707.
[15]	徐祺林, 郝少欢, 冉博. 肝硬化脾切除术后门静脉系统血栓形成的危险因素分析*[J]. 实用肝脏病杂志, 2019, 22(5): 708-711.

乙型肝炎肝硬化和肝癌患者肝组织HBV复制状态分析*

Hepatic hepatitis B virus replication status in patients with cirrhosis and primary liver cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价